EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

Anna M Becker, Aaron Klaiber, Friederike Holze, Ioanna Istampoulouoglou, Urs Duthaler, Nimmy Varghese, Anne Eckert, Matthias E Liechti iD

International Journal of Neuropsychopharmacology · 14.02.2023 · 26 (2) · 97-106

DOI: 10.1093/ijnp/pyac075 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 07.11.2022. Verfasst von Anna M Becker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Base…. Hauptthemen laut MEDLINE: Hallucinogens. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lysergic acid diethylamide (LSD) is currently being investigated in psychedelic-assisted therapy. LSD has a long duration of acute action of 8–11 hours. It produces its acute psychedelic effects via stimulation of the serotonin 5-hydroxytryptamine-2A (HT2A) receptor. Administration of the 5-HT2A antagonist ketanserin before LSD almost fully blocks the acute subjective response to LSD. However, unclear is whether ketanserin can also reverse the effects of LSD when administered after LSD.

Methods

We used a double-blind, randomized, placebo-controlled, crossover design in 24 healthy participants who underwent two 14-hour sessions and received ketanserin (40 mg p.o.) or placebo 1 hour after LSD (100 µg p.o.). Outcome measures included subjective effects, autonomic effects, acute adverse effects, plasma brain-derived neurotrophic factor levels, and pharmacokinetics up to 12 hours.

Results

Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 hours with placebo to 3.5 hours. Ketanserin also reversed LSD-induced alterations of mind, including visual and acoustic alterations and ego dissolution. Ketanserin reduced adverse cardiovascular effects and mydriasis that were associated with LSD but had no effects on elevations of brain-derived neurotrophic factor levels. Ketanserin did not alter the pharmacokinetics of LSD.

Conclusions

These findings are consistent with an interaction between ketanserin and LSD and the view that LSD produces its psychedelic effects only when occupying 5-HT2A receptors. Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy. Trial registry ClinicalTrials.gov (NCT04558294)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HallucinogensHumansKetanserinLysergic Acid DiethylamideCross-Over StudiesBrain-Derived Neurotrophic FactorHealthy VolunteersDouble-Blind Method

Stichwörter der Autor:innen

LSDinteractionketanserinpharmacokineticssubjective effects

Substanzen

KetanserinHallucinogensLysergic Acid DiethylamideBrain-Derived Neurotrophic Factor

Autor:innen und Institutionen

  • Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
  • Psychiatric University Hospital, University of Basel, Basel, Switzerland.
  • Transfaculty Research Platform Molecular and Cognitive Neuroscience, University of Basel, Basel, Switzerland.

ORCID-Profile: Matthias E Liechti

Zitieren

APA

Becker, A. M., Klaiber, A., Holze, F., Istampoulouoglou, I., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2023). Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. International Journal of Neuropsychopharmacology, 26(2), 97-106. https://doi.org/10.1093/ijnp/pyac075

Vancouver

Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. International Journal of Neuropsychopharmacology. 2023;26(2):97-106. doi:10.1093/ijnp/pyac075

BibTeX
@article{Becker2023,
  author = {Becker, Anna M and Klaiber, Aaron and Holze, Friederike and Istampoulouoglou, Ioanna and Duthaler, Urs and Varghese, Nimmy and Eckert, Anne and Liechti, Matthias E},
  title = {Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2023},
  volume = {26},
  number = {2},
  pages = {97--106},
  doi = {10.1093/ijnp/pyac075}
}
Kostenlos starten →